DUBLIN--(BUSINESS WIRE)--Jul 23, 2019--

Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. Approximately 1 in 7 men will be diagnosed with prostate cancer in their lifetime.

This report provides an in-depth analysis of the Global Prostate Cancer Diagnostics and Minimally Invasive Treatments Market, estimated at nearly $1 billion in combined sales in 2018. The total market is forecast to experience healthy growth of more than 10% CAGR.

The market will be driven by new and promising non-invasive diagnostic tests, such as emerging molecular diagnostics/liquid biopsy technologies used to help to rule out biopsy, or prevent unnecessary biopsies, in low-risk prostate cancer patients. These improved assays will continue to spur market momentum and supplement, or perhaps someday replace less-than reliable PSA tests.

Other new diagnostics technologies, such as targeted prostate biopsy using MRI-ultrasound (MRI-US) fusion, is allowing accurate diagnosis of serious tumors not typically found with conventional biopsy, while providing a method for repeat biopsy of specific tumor-bearing sites for men in active surveillance. Fusion devices are allowing the urologist to combine MRI and other images to more accurately guide prostate biopsy in an outpatient clinic setting.

Several minimally invasive prostate cancer treatment products will also spur market growth, including instruments and accessories used in robotic-assisted laparoscopic prostatectomy (RALP); brachytherapy products; ablation systems (particularly, high-intensity focused ultrasound/HIFU and cryoablation); and novel hydrogel spacers for protecting healthy tissue during prostate radiotherapy.

The report provides the following useful information:

  • an epidemiological overview of prostate cancer
  • analysis of selected leading diagnostic and minimally invasive treatment products for prostate cancer
  • competitive analysis, including estimated market share and emerging competition
  • insight into factors driving and limiting market growth
  • estimated five-year market forecasts

Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries.

Key Topics Covered

Executive Summary

i. Prostate cancer overview

ii. Prostate cancer diagnostics and minimally invasive treatments market

Exhibit ES-1: Prostate cancer diagnostic products, global market forecast 2018-23

Exhibit ES-2: Minimally invasive prostate cancer treatments, global market forecast 2018-23

a. Market drivers and limiters

b. Technology trends

c. Market leaders

d. Competitive strategies

e. Emerging competition

iii. Methodology

iv. Bibliography

1. Prostate Cancer Overview

1.1 Staging

1.2 Incidence: US, 5EU, and Japan

Exhibit 1-1: Estimated new cases of prostate cancer by stage, US, 2018 and 2023

Exhibit 1-2: Estimated new cases of prostate cancer by stage, 5EU, 2018 and 2023

Exhibit 1-3: Estimated new cases of prostate cancer by stage, Japan, 2018 and 2023

1.3 Risk factors

1.3.1 Genetics

1.4 Detection and diagnosis

1.4.1 PSA testing

1.4.2 Screening

1.4.3 Biopsy

Exhibit 1-4: Advantages and disadvantages of multi-parametric MRI for prostate imaging

1.4.4 Molecular diagnostics and liquid biopsy

Exhibit 1-5: Advantages and disadvantages of liquid biopsy

1.5 Prostate cancer treatment pathways

Exhibit 1-6: Treatment options for prostate cancer by cancer type/stage

1.5.1 Surgery

For more information about this report visit https://www.researchandmarkets.com/r/5xw6uw

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diagnostics,Prostate Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 07/23/2019 06:45 AM/DISC: 07/23/2019 06:45 AM

Copyright Business Wire 2019.